In this article, we will be taking a look at the 5 Most Promising Cancer Stocks According to Wall Street Analysts. If you wish to see the full list, visit 10 Most Promising Cancer Stocks According to Wall Street Analysts.
5. Janux Therapeutics, Inc. (NASDAQ:JANX)
Price Target Upside: 98.90%
Janux Therapeutics, Inc. (NASDAQ:JANX) is one of the most promising stocks on our list.
TheFly reported on June 25 that Truist Securities initiated coverage of JANX with a Buy recommendation and a $26 price target, revised lower from $80. The firm highlighted the need for additional improvements in the tolerability and durability profile of JANX007 while viewing the program as important validation for Janux’s TRACTr platform. Truist also identified potential growth opportunities from additional pipeline candidates, including JANX014, JANX013, and JANX011, which broaden the platform’s applications across oncology and autoimmune conditions.
Earlier on June 23, Janux Therapeutics, Inc. (NASDAQ:JANX) disclosed through an SEC filing that William Go, M.D., Ph.D., had stepped down from his role as Chief Medical Officer. The company stated that his departure was classified as a termination without “Cause” under its Change in Control and Severance Benefit Plan. JANX has started the search process for a replacement, while members of its current clinical leadership team will temporarily oversee responsibilities previously managed by Dr. Go. The company emphasized that the transition does not impact its development strategy, regulatory objectives, or previously announced clinical timelines. JANX also noted that Dr. Go’s departure was not related to any operational, policy, or practice disagreements with the company.
Janux Therapeutics, Inc. (NASDAQ:JANX) is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies designed to target cancer cells while reducing systemic toxicity.
4. Silence Therapeutics plc (NASDAQ:SLN)
Price Target Upside: 150.00%
Silence Therapeutics plc (NASDAQ:SLN) is one of the most promising stocks on our list.
TheFly reported on June 24 that Cantor Fitzgerald analyst Prakhar Agrawal initiated coverage of SLN with an Overweight rating and no price target. The firm highlighted Silence as a clinical-stage biotechnology company developing siRNA-based therapies targeting hematologic, cardiometabolic, and rare diseases. Cantor identified divesiran as a key catalyst, with Phase 2 polycythemia vera data expected in August. The firm expressed confidence in the upcoming results, expecting Divesiran to potentially demonstrate strong efficacy with dosing advantages. Cantor views Silence as undervalued at its current market capitalization of approximately $300 million, with its valuation analysis suggesting more than 160% potential upside and an attractive risk-reward profile ahead of the clinical update.
On June 11, Silence Therapeutics plc (NASDAQ:SLN) presented follow-up and quality-of-life findings from the Phase 1 SANRECO study evaluating divesiran, an siRNA therapy targeting TMPRSS6, in 21 patients with polycythemia vera who required phlebotomy. Data presented at the EHA 2026 Annual Congress showed continued reductions in phlebotomy needs, improved disease-related symptoms, and better quality-of-life measures. During treatment, patients required only 5 phlebotomies compared with 80 in the six months before enrollment, with reduced treatment needs continuing after the final dose. Divesiran was generally well tolerated, supporting further evaluation in the ongoing Phase 2 SANRECO study, which is expected to provide topline results in August 2026.
Silence Therapeutics plc (NASDAQ:SLN) is a clinical-stage biotechnology company developing siRNA-based precision medicines to silence disease-causing genes across hematology, cardiovascular, and rare diseases.
3. BridgeBio Oncology Therapeutics, Inc. (NASDAQ:BBOT)
Price Target Upside: 199.09%
BridgeBio Oncology Therapeutics, Inc. (NASDAQ:BBOT) is one of the most promising stocks on our list.
TheFly reported on June 22 that Oppenheimer initiated coverage of BBOT with an Outperform rating and a $22 price target. The firm highlighted the company’s differentiated oncology pipeline focused on multiple RAS-targeted programs, led by BBO-8520, which is viewed as a potential leading KRAS G12C therapy based on encouraging response data and liver safety results in non-small cell lung cancer. Oppenheimer also noted early potential from additional programs, including BBO-10203 and BBO-11818. With approximately $389 million in cash expected to support operations through 2028, the firm stated that financing concerns are not the main risk factor.
Separately, on May 12, BridgeBio Oncology Therapeutics, Inc. (NASDAQ:BBOT) released its first-quarter 2026 financial results alongside a business update highlighting continued pipeline advancement. The company ended the quarter with $388.9 million in cash, cash equivalents, and marketable securities, which it expects will fund operations into 2028. Research and development spending increased to $39.8 million from $20.6 million a year earlier, driven by clinical and manufacturing activities for BBO-8520, BBO-11818, and BBO-10203. General and administrative expenses rose to $6.4 million from $2.5 million, while quarterly net loss widened to $42.1 million compared with $22.1 million in the prior-year period.
BridgeBio Oncology Therapeutics, Inc. (NASDAQ:BBOT) is a clinical-stage biopharmaceutical company developing small-molecule therapies targeting RAS, PI3Kα, and other cancer-driving mutations.
2. Cardiff Oncology, Inc. (NASDAQ:CRDF)
Price Target Upside: 395.87%
Cardiff Oncology, Inc. (NASDAQ:CRDF) is one of the most promising stocks on our list.
TheFly reported on June 5 that Lucid Capital analyst Christopher Liu reduced the price target on CRDF to $4 from $10 while reaffirming a Buy rating. The revised target reflected uncertainty surrounding an ongoing licensing dispute with Nerviano Medical Sciences involving ownership rights to onvansertib. Despite the legal overhang, the firm believes both companies have strong incentives to resolve the issue in the near future. Lucid Capital also indicated that investor attention could shift back to Cardiff’s clinical progress, with future onvansertib data potentially catalyzing a recovery in the company’s share price.
In addition to that, on June 2, Cardiff Oncology, Inc. (NASDAQ:CRDF) reported data from the Phase 2 CRDF-004 trial evaluating onvansertib with standard chemotherapy in first-line RAS-mutated metastatic colorectal cancer. The 30 mg onvansertib plus FOLFIRI/bevacizumab regimen, selected for Phase 3 development, delivered stronger tumor responses and longer progression-free survival than standard treatment without increasing safety concerns. The combination achieved a 72.2% confirmed objective response rate versus 42.1% for standard therapy alone. Following discussions with the FDA, the company finalized the design of its registrational Phase 3 study, which will evaluate the same regimen as first-line treatment for patients with RAS-mutated metastatic colorectal cancer.
Cardiff Oncology, Inc. (NASDAQ:CRDF) is a clinical-stage biotechnology company developing precision cancer therapies, led by onvansertib, a PLK1 inhibitor designed to overcome treatment resistance.
1. Heron Therapeutics, Inc. (NASDAQ:HRTX)
Price Target Upside: 631.71%
Heron Therapeutics, Inc. (NASDAQ:HRTX) is one of the most promising stocks on our list.
TheFly reported on June 3 that H.C. Wainwright lowered its price target on HRTX to $2 from $4 while maintaining a Buy rating after the U.S. District Court for the District of Delaware ruled against the company in its Cinvanti patent litigation. Although the decision was viewed as a setback for HRTX’s intellectual property protections, the firm noted that the company intends to appeal the ruling to the U.S. Court of Appeals for the Federal Circuit, citing confidence in the strength of its legal arguments and the potential for the decision to be overturned.
The revised price target followed HRTX’s June 2 announcement that the Delaware court had invalidated two patents covering its Cinvanti injectable emulsion in litigation involving Azurity Pharmaceuticals and Slayback Pharma. The company emphasized that the ruling does not affect previously executed settlement agreements related to either Cinvanti or Aponvie injectable emulsion. Heron also reaffirmed its plan to challenge the decision before the Federal Circuit, which has jurisdiction over patent appeals, underscoring its commitment to defending its intellectual property despite the unfavorable district court ruling.
Heron Therapeutics, Inc. (NASDAQ:HRTX) is a commercial-stage biotechnology company developing innovative therapies for acute care and oncology using proprietary drug delivery technologies.
While we acknowledge the potential of HRTX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than HRTX and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 10 Best Future Stocks to Buy and Hold for 10 Years and 10 Most Promising Long-Term Stocks to Buy According to Analysts.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
